Summary
Cannot evaluate alignment to FDA-approved prescribing information because no actual FDA Prescribing Information text (with FDA section identifiers such as contraindications/boxed warnings/warnings/drug interactions) was provided; only consumer-style sections and a claim of inability to retrieve the label were included.
Category Scores
Accurate Statements
The product is used to loosen phlegm (mucus) and thin bronchial secretions to make coughs more productive.
Supported by supplied text under “USE(S)” (no FDA prescribing section number provided).
Do not use for children under 12 years of age.
Supported by supplied text under “DO NOT USE for children under 12 years of age” (no FDA prescribing section number provided).
Ask a doctor before use if cough is persistent/chronic such as occurs with smoking, asthma, chronic bronchitis, or emphysema or if cough is accompanied by too much phlegm (mucus).
Supported by supplied text under “ASK A DOCTOR BEFORE USE IF YOU HAVE …” (no FDA prescribing section number provided).
Stop use and ask a doctor if cough lasts more than 7 days, comes back, or occurs with fever, rash, or persistent headache.
Supported by supplied text under “STOP USE AND ASK A DOCTOR IF …” (no FDA prescribing section number provided).
Directions include: do not crush, chew, or break tablet; take with a full glass of water; adults and children 12 years of age and over: 1 or 2 tablets every 12 hours; do not exceed 4 tablets in 24 hours; children under 12 years of age: do not use.
Supported by supplied text under “DIRECTIONS” (no FDA prescribing section number provided).
Unsupported Statements
The provided paste appears to be consumer-facing “Drug Facts”-style labeling rather than FDA “Prescribing Information” sections, and it cannot be verified it matches the most recent FDA-approved prescribing information for the exact product/NDC.
No FDA label content or NDC-specific FDA prescribing information was provided to substantiate the verification status; the statement is an assertion about inability to retrieve/verify rather than a label-supported claim.
Contradictions
Important Omissions
FDA Prescribing Information elements relevant to a full audit were not provided (e.g., Boxed Warnings, Contraindications, Warnings and Precautions, Drug Interactions, Adverse Reactions, Storage/handling, and full FDA section identifiers).
Importance:
High
No discrete user-specified evaluated claim was provided beyond general label statements; therefore an on-label claim-to-label verification cannot be completed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response does not complete an FDA label alignment audit and omits major FDA prescribing information sections; while the provided dosing/age and cough-duration criteria are internally consistent with the pasted text, the lack of FDA Prescribing Information prevents determining overall label compliance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
No FDA-approved Prescribing Information content was supplied for comparison; only partial consumer-style label sections were provided, preventing label alignment verification.
Suggested Improvement
Provide the exact FDA-approved prescribing information text (or DailyMed/FDA label excerpts) including FDA section identifiers (Boxed Warnings, Contraindications, Warnings & Precautions, Drug Interactions, Adverse Reactions, etc.) for the specific product/NDC, then supply the specific claim to evaluate.